Viewing Study NCT01454544



Ignite Creation Date: 2024-05-05 @ 11:57 PM
Last Modification Date: 2024-10-26 @ 10:42 AM
Study NCT ID: NCT01454544
Status: COMPLETED
Last Update Posted: 2017-01-30
First Post: 2011-10-13

Brief Title: A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet
Sponsor: ALK-Abelló AS
Organization: ALK-Abelló AS

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2017-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MT-06
Brief Summary: The primary aim of this trial is to evaluate the efficacy of the ALK house dust mite tablet given once daily compared to a placebo tablet in the treatment of house dut mite allergic rhinits

Additionally the secondary objective of the trial is to evaluate the safety and tolarability of the ALK house dust mite tablet

Immunotherapy has been shown to provide therapeutic benefits to subjects with house dust mite induced allergy This trial is planned to investigate if clinically relevant improvements in rhinitis symptoms and with less use of symptomatic medication can be obtained in subjects with a history of poor didease control despite of use of symptomatic medications
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2011-002277-38 EUDRACT_NUMBER None None